Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mirati Therapeutics Inc.
CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are at least 18 years old (or old enough to legally make their own treatment decisions, according to local laws).
Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation.
Have had previous treatment with 1) chemotherapy that included a drug called cisplatin or a drug called carboplatin and 2) a type of drug called an immune checkpoint inhibitor.
Have recovered from their prior treatment and blood tests are within a safe range.
Have certain medical conditions or need to take certain medications that, in the opinion of a trial doctor, could make it unsafe for them to participate or difficult to complete the trial assessments, or are pregnant.
You may not be if
Have had previous treatment with a drug that targets KRAS G12C.
Have cancer that can potentially be removed with surgery.
Clareo Health | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
